- Home
- EVGO vs CTNM Comparison
EVGO vs CTNM Comparison
Compare EVGO & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVGO | CTNM |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.1M | 416.1M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | EVGO | CTNM |
|---|---|---|
| Price | $3.05 | $14.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | $5.70 | ★ $18.60 |
| AVG Volume (30 Days) | ★ 3.3M | 246.0K |
| Earning Date | 03-03-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $333,129,000.00 | N/A |
| Revenue This Year | $45.34 | N/A |
| Revenue Next Year | $31.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.21 | N/A |
| 52 Week Low | $2.20 | $3.35 |
| 52 Week High | $5.18 | $13.53 |
Technical Indicators
Market Signals| Indicator | EVGO | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 46.30 | 72.23 |
| Support Level | $2.93 | $11.00 |
| Resistance Level | $3.23 | $13.53 |
| Average True Range (ATR) | 0.15 | 0.90 |
| MACD | 0.01 | 0.36 |
| Stochastic Oscillator | 42.19 | 99.36 |
Price Performance
Historical ComparisonAbout EVGO EVgo Inc.
EVgo owns and operates a public direct current fast-charging network in the US. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the US. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners to locate and deploy its EV charging infrastructure.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.